Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL112 in acute myocardial infarction with moderate renal impairment
2015-003017-26Phase 2Completed
- Sponsor
- CSL Behring
- Start
- Mar 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing CSL112 with Placebo (2 arms). Primary endpoint: Incidence of treatment-emergent renal serious adverse event. Started Mar 2016; status: completed.
02
Drugs
CSL112
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2015-003017-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003017-26.